Bexarotene
Total Payments
$554,029
Transactions
3
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $263,286 | 1 | 0 |
| 2017 | $290,743 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $554,029 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Bexarotene Pivotal Fed Study | West-Ward Pharmaceuticals | $263,286 | 0 |
| Bexarotene Fed Pivotal Study | West-Ward Pharmaceuticals | $178,777 | 0 |
| Bexarotene Fed Pilot Study | West-Ward Pharmaceuticals | $111,966 | 0 |
Top Doctors Receiving Payments for Bexarotene
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Austin, TX | $554,029 | 3 |
Ad
Manufacturing Companies
- West-Ward Pharmaceuticals $554,029
Product Information
- Type Drug
- Total Payments $554,029
- Total Doctors 0
- Transactions 3
About Bexarotene
Bexarotene is a drug associated with $554,029 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is West-Ward Pharmaceuticals.
Payment data is available from 2017 to 2018. In 2018, $263,286 was paid across 1 transactions to 0 doctors.
The most common payment nature for Bexarotene is "Unspecified" ($554,029, 100.0% of total).
Bexarotene is associated with 3 research studies, including "Bexarotene Pivotal Fed Study" ($263,286).